MRgFUS subthalamotomy in Parkinson’s disease: An approach aimed at minimizing Lesion Volume

Focused ultrasound subthalamotomy (MRgFUS) is a promising new treatment for Parkinson’s disease that uses precise, non-invasive technology to create small lesions in the subthalamic nucleus (STN). This technique aims to improve motor symptoms such as tremor, stiffness, and slowness of movement. By targeting smaller lesions, MRgFUS may lower the risk of side effects compared to older methods like radiofrequency ablation. In this study, patients showed significant improvement, with over 50% reduction in symptoms like tremor (64.4%), stiffness (58.3%), and slowness (52.3%) six months after the procedure. Smaller lesion sizes, averaging 95.9 mm³, were used compared to earlier studies that targeted larger areas, which may contribute to fewer complications. Side effects were generally mild and temporary, though some patients experienced mild involuntary movements (dyskinesia), and ongoing medication was still needed. While these results align with findings from other studies, there is still much to learn about optimizing the procedure. The study emphasizes the importance of understanding the functional roles of the STN and related brain areas to refine targeting and improve outcomes. Although the study had limitations, including a small sample size and short follow-up period, it supports MRgFUS as a potentially safer and effective option for people with advanced Parkinson’s disease who do not respond well to medication. Future research will focus on improving the technique, ensuring long-term safety, and exploring the best ways to tailor this treatment to individual patients.